Hints and tips:
...UBS recommended last week in a research note that investors should avoid UCB of Belgium because of relatively low cash flow and short-term refinancing of debts incurred during its purchase of Schwarz Pharma...
...UCB , reporting its first figures to include its takeover of Schwarz Pharma, also shook off the bearish market....
...The latest acquisition in European pharmaceuticals, UCB’s €4.4bn agreed offer for Germany’s Schwarz Pharma, replays the same themes: the targets are privately controlled, mid-sized speciality pharma companies...
...UCB, the Belgian drug-maker, climbed 4 per cent to €48.90. It reported positive clinical trials for two new epilepsy medicines a day after its €4.4bn cash and share offer for Schwarz Pharma....
...Following Merck’s bid for Serono, UCB of Belgium yesterday launched a €4.4bn bid for Schwarz Pharma. Analysts say Shire could be a target for US peers Medlmmune or Forest Labs....
International Edition